Key result
Among 756 Turkish patients with atrial fibrillation in the GARFIELD-AF registry, all-cause mortality was higher compared to global data despite lower mean stroke and bleeding risk scores.
Why the study?
Stroke prevention with fewer adverse effects is central to AF therapy, motivating comparison of treatment strategies and everyday stroke prevention practice in Turkey with other populations.
Cohort (n=756)
Yes
Turkish AF patients exhibit distinct antithrombotic treatment patterns, including higher FXa inhibitor use and frequent switching to antiplatelets at high bleeding risk, alongside higher all-cause mortality despite lower baseline risk scores.
May indicate unmeasured risks in Turkish AF patients; leaves open reasons for excess mortality versus global registry data.
The corner stone of atrial fibrillation therapy includes the prevention of stroke with less adverse effects. The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) study provided data to compare treatment strategies in Turkey with other populations and every-day practice of stroke prevention management with complications. METHODS: GARFIELD-AF is a large-scale registry that enrolled 52,014 patients in five sequential cohorts at >1,000 centers in 35 countries.This study initiated to track the evolution of global anticoagulation practice, and to study the impact of NOAC therapy in AF. 756 patients from 17 enrolling sites in Turkey were in cohort 4 and 5.Treatment strategies at diagnosis initiated by CHA2DS2-VASc score, baseline characteristics of patients, treatment according to stroke and bleeding risk profiles, INR values were analyzed in cohorts.Also event rates during the first year follow up were evaluated. RESULTS: AF patients in Turkey were mostly seen in young women.Stroke risk according to the CHADS2 score and CHA2DS2-VASc score compared with world data. The mean of risk score values including HAS-BLED score were lower in Turkey than world data.The percentage of patients receiving FXa inhibitor with or without an antiplatelet usage was more than the other drug groups. All-cause mortality was higher in Turkey. Different form world data when HAS-BLED score was above 3, the therapy was mostly changed to antiplatelet drugs in Turkey. CONCLUSION: The data of GARFIELD-AF provide data from Turkey about therapeutic strategies, best practices also deficiencies in available treatment options, patient care and clinical outcomes of patients with AF.
No takes yet. Share an insight, caveat, or question.
Begüm Yetiş Sayın (2019) conducted a cohort in Atrial fibrillation (n=756). Antithrombotic treatment patterns vs. Global GARFIELD-AF population was evaluated on All-cause mortality and event rates at 1 year. Among 756 Turkish patients with atrial fibrillation in the GARFIELD-AF registry, all-cause mortality was higher compared to global data despite lower mean stroke and bleeding risk scores.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: